MA28609B1 - Vaccins - Google Patents

Vaccins

Info

Publication number
MA28609B1
MA28609B1 MA29491A MA29491A MA28609B1 MA 28609 B1 MA28609 B1 MA 28609B1 MA 29491 A MA29491 A MA 29491A MA 29491 A MA29491 A MA 29491A MA 28609 B1 MA28609 B1 MA 28609B1
Authority
MA
Morocco
Prior art keywords
vaccines
Prior art date
Application number
MA29491A
Other languages
English (en)
Inventor
Patrick Chomez
Catherine Pascaline Anne Ghislaine Collignon
Mechelen Marcelle Paulette Van
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA28609B1 publication Critical patent/MA28609B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA29491A 2004-05-21 2006-11-28 Vaccins MA28609B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0411411.2A GB0411411D0 (en) 2004-05-21 2004-05-21 Vaccines

Publications (1)

Publication Number Publication Date
MA28609B1 true MA28609B1 (fr) 2007-05-02

Family

ID=32607764

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29491A MA28609B1 (fr) 2004-05-21 2006-11-28 Vaccins

Country Status (16)

Country Link
US (1) US20080069832A1 (fr)
EP (1) EP1761275A2 (fr)
JP (1) JP2007538044A (fr)
KR (1) KR20070029730A (fr)
CN (1) CN1956729A (fr)
AU (1) AU2005244615A1 (fr)
BR (1) BRPI0511185A (fr)
CA (1) CA2564778A1 (fr)
GB (1) GB0411411D0 (fr)
IL (1) IL178890A0 (fr)
MA (1) MA28609B1 (fr)
MX (1) MXPA06013386A (fr)
NO (1) NO20065304L (fr)
RU (1) RU2006139424A (fr)
WO (1) WO2005112991A2 (fr)
ZA (1) ZA200609500B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201001322A1 (ru) 2005-03-31 2011-02-28 Глаксосмитклайн Байолоджикалс С.А. Вакцины против хламидиоза
ATE543832T1 (de) 2005-04-29 2012-02-15 Glaxosmithkline Biolog Sa Verfahren zur vorbeugung oder behandlung einer m.-tuberculosis-infektion
EA200702254A1 (ru) * 2005-05-19 2008-06-30 Глаксосмитклайн Байолоджикалс С.А. Вакцинная композиция, содержащая в-субъединицу термолабильного токсина e.coli и антиген и адъювант
GB0524409D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
EP2013227A4 (fr) * 2006-05-09 2010-07-28 Jackson H M Found Military Med Compositions immunogènes anti-vih-1
EP1938836A1 (fr) * 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprenant une sous-unité B de la toxine dysentérique et moyen de stimulation des cellules NKT
KR20110091817A (ko) 2007-05-24 2011-08-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 동결건조 항원 조성물
GB0724357D0 (en) * 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
WO2009126819A1 (fr) * 2008-04-09 2009-10-15 Advanced Immune Therapeutics, Inc. Procédé pour améliorer la bioactivité d'anticorps d'ige thérapeutiques, pour le traitement d'une maladie
WO2010115229A1 (fr) * 2009-04-09 2010-10-14 The University Of Melbourne Composition immunogénique et utilisations de celle-ci
AU2009344150B2 (en) * 2009-04-09 2014-10-09 Innavac Pty Ltd Immunogenic composition and uses thereof
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
AR077636A1 (es) 2009-07-08 2011-09-14 Abbott Biologicals Bv Vacuna viral y uso de la misma
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056883B4 (de) * 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CL2012001399A1 (es) * 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
CN104688687A (zh) 2009-12-03 2015-06-10 诺华股份有限公司 疫苗佐剂制备中的亲水过滤
KR101523215B1 (ko) * 2009-12-03 2015-05-27 노파르티스 아게 에멀션 미세 액화 및/또는 균질화 동안 성분들의 순환
EP3520814A1 (fr) 2010-09-22 2019-08-07 Ena Therapeutics Pty Ltd Composition immunstimulatrice
EP3593813A1 (fr) 2010-12-14 2020-01-15 GlaxoSmithKline Biologicals S.A. Composition antigénique de mycobacterium
CN102161998B (zh) * 2011-01-14 2013-01-09 中国人民解放军军事医学科学院附属医院 基于b7-1-pe40kdel外毒素融合基因的dna疫苗及其用途
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
BR112014001052A2 (pt) * 2011-07-22 2017-02-21 Glaxosmithkline Biologicals Sa método para reduzir a agregação de uma proteína, uso de uma composição polianiônica, composição, e, método e processo para a produção de uma composição
EP2666785A1 (fr) 2012-05-23 2013-11-27 Affiris AG Vaccins basés sur la protéine complément C5a
EP2703483A1 (fr) 2012-08-29 2014-03-05 Affiris AG Vaccin à base de PCSK9
JP5931113B2 (ja) * 2014-04-08 2016-06-08 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
CA3045952A1 (fr) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Nouveau procede
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
KR101966346B1 (ko) * 2017-01-13 2019-04-05 전북대학교 산학협력단 시가 독소 Stx2e를 제조하는 방법 및 이를 포함하는 부종병을 예방하기 위한 백신 조성물
KR101987851B1 (ko) 2017-04-28 2019-06-11 한국생명공학연구원 장출혈성대장균 유래의 시가독소 타입 1 B-subunit으로 유도된 노인성 황반변성(AMD) 동물모델 및 이를 이용한 스크리닝 방법
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
EP3669890A1 (fr) * 2018-12-18 2020-06-24 Croda International PLC Nanoparticules filamenteuses ayant un effet d'adjuvant de vaccin
US20220388950A1 (en) 2019-06-26 2022-12-08 Axelia Oncology Pty Ltd Novel molecules
CN111333734B (zh) * 2020-03-31 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种百日咳丝状血凝素融合蛋白及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2143716T3 (es) * 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
WO1996030043A1 (fr) * 1995-03-24 1996-10-03 Ophidian Pharmaceuticals Traitement contre escherichia coli producteur de verotoxines
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1999059627A2 (fr) * 1998-05-15 1999-11-25 Green Allan M Sous-unite b de verotoxine destinee a une immunisation
PT1187629E (pt) * 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
EP1229045A1 (fr) * 2001-02-01 2002-08-07 Institut Curie Support universel pour le ciblage de molécules sur des cellules exprimant le récepteur Gb3

Also Published As

Publication number Publication date
CA2564778A1 (fr) 2005-12-01
EP1761275A2 (fr) 2007-03-14
GB0411411D0 (en) 2004-06-23
CN1956729A (zh) 2007-05-02
MXPA06013386A (es) 2007-01-23
IL178890A0 (en) 2007-03-08
KR20070029730A (ko) 2007-03-14
US20080069832A1 (en) 2008-03-20
JP2007538044A (ja) 2007-12-27
ZA200609500B (en) 2008-02-27
RU2006139424A (ru) 2008-06-27
BRPI0511185A (pt) 2007-12-04
WO2005112991A3 (fr) 2006-03-30
WO2005112991A2 (fr) 2005-12-01
NO20065304L (no) 2006-11-20
AU2005244615A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
MA28609B1 (fr) Vaccins
MA28639B1 (fr) Vaccins
MA28885B1 (fr) vaccins
DK1959991T3 (da) Terapeutisk vaccine
TWI365191B (en) Vaccine
DK1968631T3 (da) Vaccine
GB2434367B (en) Improved vaccines
ATE462445T1 (de) Prrs-impfstoffe
GB0504436D0 (en) Vaccine
ATE450271T1 (de) Impfstoff
BRPI0607474A2 (pt) vacinação enriquecida com glicosido-alquila
IS8325A (is) Bóluefni
GB0411150D0 (en) Vaccine
GB0413510D0 (en) Vaccine
GB0412407D0 (en) Vaccine
GB0428381D0 (en) Vaccine
AP2709A (en) An anti-theileriosis vaccine
GB0419918D0 (en) Vaccine
GB0406598D0 (en) Vaccine
GB0413154D0 (en) Vaccine
GB0413371D0 (en) Vaccine
GB0425339D0 (en) Vaccine
GB0412547D0 (en) Vaccine
GB0416833D0 (en) Vaccine
GB0413513D0 (en) Vaccine